Table 3. CMR measurements.
| Characteristic | Total population (n =80) | Non-LV remodeling (n=58, 72.5%) | LV remodeling (n=22, 27.5%) | χ2 | P value |
|---|---|---|---|---|---|
| LVEF baseline (%) | 50.6±8.2 | 51.9±7.9 | 47.2.0±8.2 | 2.367 | 0.020 |
| LVEDV baseline (mL) | 135.6±22.2 | 136.5±19.3 | 133.4±28.8 | 0.567 | 0.572 |
| LVEDVi baseline (mL/m2) | 74.6±12.8 | 75.1±12.2 | 73.1±14.5 | 0.614 | 0.541 |
| LVESV baseline (mL) | 67.6±18.2 | 66.1±15.9 | 71.5±23.2 | –1.195 | 0.236 |
| LVESVi baseline (mL/m2) | 37.2±10.2 | 36.4±9.5 | 39.2±11.9 | –1.068 | 0.289 |
| IS baseline (% of LVMM) | 13.5 (8.3–20.3) | 12.6 (7.7–18.1) | 18.8 (12.0–27.7) | –2.613 | 0.009 |
| Myocardial area at risk | 28.1±9.4 | 26.5±8.5 | 32.3±10.1 | –2.545 | 0.013 |
| Peak GRS | 21.8±5.6 | 21.8±5.6 | 21.9±5.7 | –0.039 | 0.969 |
| Peak GCS | –13.4 (–15.6 to –12.1) | –13.4 (–15.1 to –12.1) | –14.0 (–16.7 to –11.8) | 0.212 | 0.832 |
| Peak GLS | –12.6±4.2 | –12.4±2.0 | –13.4±2.1 | 2.026 | 0.046 |
| Myocardial native T1 value | 1353 (1303 –1409) | 1355 (1305–1414) | 1352 (1300 –1402) | –0.280 | 0.779 |
| Myocardial ECV | 35.7 (33.8–37.6) | 35.0 (33.2–36.9) | 36.5 (34.7–39.4) | –2.209 | 0.027 |
| MVO, n (%) | 4.296 | 0.038 | |||
| MVO (−) | 33 (41.3) | 28 (48.3) | 5 (22.7) | ||
| MVO (+) | 47 (58.8) | 30 (51.7) | 17 (77.3) | ||
| %ΔLVEF (%) | 6.1±14.9 | 7.9±14.7 | 1.4±14.7 | 0.824 | 0.083 |
| %ΔLVEDV (%) | 3.5 (–6.2–10.6) | –4.4 (–7.5–4.4) | 12.7 (11.0–14.4) | –9.762 | < 0.001 |
| %ΔLVESV (%) | –9.4±15.5 | –13.6±14.3 | 1.7±13.1 | –4.392 | < 0.001 |
LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; LVEDVi, left ventricular end-diastolic volume index; LVESV, left ventricular end-systolic volume; LVESVi, left ventricular end-systolic volume index; LVMM, left ventricular myocardial mass; LVMMi, left ventricular myocardial mass index; IS, infarct size; GRS, global radial strain; GCS, global circumferential strain; GLS, global longitudinal strain; ECV extracellular volume; MVO, microvascular obstruction.